TMCnet News
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain DisordersBALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that preclinical studies evaluating CTI-1601’s effects on gene expression and neurodegeneration will be featured in a poster at the upcoming Gordon Research Conference on Neurobiology of Brain Disorders. The conference will take place August 7 – 12, 2022 at the Rey Don Jaime Grand Hotel in Castelldefels, Spain. The poster, entitled, “Mitochondrial Protein Frataxin (FXN) promotes Expression of Neuronal Differentiation Markers: Effect of FXN Supplementation in a Model of Leukodystrophy,” will be available for viewing throughout the duation of the conference. The poster’s presenting author is David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics. About Larimar Therapeutics Investor Contact: Company Contact: |